158 related articles for article (PubMed ID: 15390018)
1. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Bara-Jimenez W; Dimitrova T; Sherzai A; Favit A; Mouradian MM; Chase TN
Mov Disord; 2004 Oct; 19(10):1183-6. PubMed ID: 15390018
[TBL] [Abstract][Full Text] [Related]
2. The dopamine transporter: importance in Parkinson's disease.
Nutt JG; Carter JH; Sexton GJ
Ann Neurol; 2004 Jun; 55(6):766-73. PubMed ID: 15174010
[TBL] [Abstract][Full Text] [Related]
3. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
[TBL] [Abstract][Full Text] [Related]
4. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
Bara-Jimenez W; Bibbiani F; Morris MJ; Dimitrova T; Sherzai A; Mouradian MM; Chase TN
Mov Disord; 2005 Aug; 20(8):932-6. PubMed ID: 15791634
[TBL] [Abstract][Full Text] [Related]
5. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
[TBL] [Abstract][Full Text] [Related]
6. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Nutt JG; Carter JH; Carlson NE
Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
[TBL] [Abstract][Full Text] [Related]
7. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
[TBL] [Abstract][Full Text] [Related]
8. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
9. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
10. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
11. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
12. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Olanow CW; Alberts MJ
Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
[No Abstract] [Full Text] [Related]
13. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
14. Milacemide therapy for Parkinson's disease.
Giuffra ME; Sethy VH; Davis TL; Mouradian MM; Chase TN
Mov Disord; 1993; 8(1):47-50. PubMed ID: 8380487
[TBL] [Abstract][Full Text] [Related]
15. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
Mizuno Y; Yanagisawa N; Kuno S; Yamamoto M; Hasegawa K; Origasa H; Kowa H;
Mov Disord; 2003 Oct; 18(10):1149-56. PubMed ID: 14534919
[TBL] [Abstract][Full Text] [Related]
17. Pramipexole, ropinirole, and mania in Parkinson's disease.
Singh A; Althoff R; Martineau RJ; Jacobson J
Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
[No Abstract] [Full Text] [Related]
18. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
19. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I;
Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525
[TBL] [Abstract][Full Text] [Related]
20. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]